Ignite Creation Date:
2024-05-06 @ 4:15 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04924257
Status:
WITHDRAWN
Last Update Posted:
2022-08-05
First Post:
2021-06-07
Brief Title:
ECT vs Esketamine
Sponsor:
Medical University Innsbruck
Organization:
Medical University Innsbruck
Study Overview
Official Title:
Electroconvulsive Therapy vs Esketamine Nasal Spray in Treatment-resistant Depression a Longitudinal Randomized Efficacy Comparison Pilot Study
Status:
WITHDRAWN
Status Verified Date:
2021-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
No eligible participants
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ETES
Brief Summary:
Treatment-resistant depression TRD is a common cause of disability and one of the most common psychiatric disorders worldwide
Electroconvulsive therapy ECT is currently the most effective treatment for TRD Recent developments showed esketamine to be a rapid-acting and effective antidepressant drug and it has been hailed as a breakthrough in treating TRD Common treatment algorithms for TRD list ECT as a treatment option but esketamine has not yet found its exact position in those algorithms
To the investigators knowledge a longitudinal randomized controlled trial comparing the efficacy of ECT and intranasal esketamine in TRD patients has not been conducted Furthermore the investigators intend to measure effects of ECT and intranasal esketamine on brain connectivity and structure using functional magnetic resonance imaging fMRI
In this study inpatients with TRD at the University Hospital for Psychiatry I Medical University Innsbruck will be randomized to ECT or intranasal esketamine Short- and medium-term treatment effects on functional and structural connectivity in the brain will be determined using fMRI
Electroconvulsive therapy ECT is currently the most effective treatment for TRD Recent developments showed esketamine to be a rapid-acting and effective antidepressant drug and it has been hailed as a breakthrough in treating TRD Common treatment algorithms for TRD list ECT as a treatment option but esketamine has not yet found its exact position in those algorithms
To the investigators knowledge a longitudinal randomized controlled trial comparing the efficacy of ECT and intranasal esketamine in TRD patients has not been conducted Furthermore the investigators intend to measure effects of ECT and intranasal esketamine on brain connectivity and structure using functional magnetic resonance imaging fMRI
In this study inpatients with TRD at the University Hospital for Psychiatry I Medical University Innsbruck will be randomized to ECT or intranasal esketamine Short- and medium-term treatment effects on functional and structural connectivity in the brain will be determined using fMRI
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None